Edit |   |
---|---|
Product Name | Flumatinib |
Description | A Bcr-Abl inhibitor (IC50 = 1.2 nM); selective for Bcr-Abl over VEGFR2, c-Src, EGFR, and HER2 at 1 µM but does inhibit PDGFRβ and c-Kit (IC50s = 307.6 and 665.5 nM, respectively); inhibits the proliferation of K562 cells expressing wild-type Bcr-Abl (IC50 = 5.1 nM) and 32D cells expressing the Bcr-Abl mutations Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblE255K, Bcr-AblM351T, and Bcr-AblH396P (IC50s = 76.3, 40.4, 123.2, 20.2, and 34.6 nM, respectively), which are resistant to imatinib; induces tumor regression and increases survival time in a K562 mouse xenograft model at 75 mg/kg per day; increases the viability of SARS-CoV-2-infected Vero E6 cells (EC50 = 1.6 µM) |
Size | 25 mg |
Concentration | n/a |
Applications | n/a |
Other Names | HH-GV-678 |
Gene, Accession, CAS # | CAS: 895519-90-1 |
Catalog # | 36226-25 |
Price | $108.00 |
Order / More Info | Flumatinib from CAYMAN CHEMICAL COMPANY |
Product Specific References | n/a |